Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 33,794,672	$ 35,300,805
Receivable due from collaboration agreement	1,628,703
Research and development tax incentive receivable	966,646
Prepaid assets and other current assets	2,447,930	2,258,229
Total current assets	38,837,951	37,559,034
Property and equipment, net	1,859,860	1,102,808
Total assets	40,697,811	38,661,842
Current liabilities:
Accounts payable	1,493,842	1,297,725
Accrued compensation	416,910
Deferred research grant revenue	50,000	24,315
Total liabilities	1,960,752	1,322,040
Commitments and contingencies (see Note 4)
Stockholders’ equity:
Common stock; $0.001 par value, 45,000,000 shares authorized; 25,371,781 and 22,534,874 shares issued and outstanding as of December 31, 2021 and 2020, respectively	25,372	22,535
Additional paid-in capital	104,078,968	71,648,453
Accumulated other comprehensive loss	(48,921)	(51,538)
Accumulated deficit	(65,318,360)	(34,279,648)
Total stockholders’ equity	38,737,059	37,339,802
Total liabilities and stockholders’ equity	$ 40,697,811	$ 38,661,842